Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?
J&J has more than 28 sources of blockbuster revenue.
Overview
Johnson & Johnson (NYSE: JNJ) has been a top-performing stock this year. Investors, in many cases rotating out of riskier assets, have looked for companies with a strong track record of earnings growth, solid competitive positions, and a revenue stream they can count on -- and J&J fits the bill.
As a healthcare player, J&J sells pharmaceuticals and medical devices that ensure a certain level of revenue, as patients need their procedures no matter what direction the stock market takes. Over time, the company's in-house research and acquisitions have built a market-leading portfolio that has kept earnings climbing. Investors, concerned about geopolitical uncertainties and risks to the artificial intelligence (AI) growth story, turned to J&J in the first half, sending the stock to a 22% gain.
Details
Last week, J&J delivered a blowout earnings report and increased full-year forecasts. But is it too late to buy this healthcare giant? Let's find out.
Source
Originally published at www.fool.com.